{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-122786","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2025-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.043989+00:00","generated_at":"2026-05-16T12:34:59.647316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"confidence":"high","headline":"Outlook Therapeutics FY2025 net loss $62.4M; $1.4M revenue from LYTENAVA launch in Europe","bullets":["Net loss $62.4M ($1.79/share) vs $75.4M ($4.06/share) prior year; revenue $1.4M from initial EU sales.","Cash $8.1M at Sept 30, 2025; $14.9M net from ATM after quarter-end; no debt mentioned.","Expenses fell $4.6M YoY due to lower R&D, partly offset by higher SG&A for European launch.","FDA PDUFA goal date for ONS-5010 is Dec 31, 2025; awaiting U.S. approval decision.","LYTENAVA accepted into UK tender framework in Dec 2025; launch expanding to Austria and Netherlands."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-122786","json":"https://secwatch.observer/filing/0001104659-25-122786.json","markdown":"https://secwatch.observer/filing/0001104659-25-122786.md","text":"https://secwatch.observer/filing/0001104659-25-122786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/0001104659-25-122786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:34:59.647316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}